Cannabis has been around for 10,000 years, but it is “new” in the sense of coming to Western medicine.
Now, with the easing of DEA restrictions, we may see much more research produced more quickly, showing cannabis’s potential as a versatile, nontoxic, inexpensive medication in comparison to currently accepted pharmaceuticals.
Cannabis research is CAMO’s backbone. We are committed to both conducting and facilitating research to assess the safety and efficacy of cannabis and cannabis compounds for the treatment medical conditions.
Completed studies have consistently shown that medical cannabis can help patients suffering from certain serious medical conditions by alleviating pain and improving their quality of life. Many researchers believe cannabis has even greater potential in the treatment of major disorders including Alzheimer’s, cancer, epilepsy, PTSD, and autoimmune diseases.
Think about it: If there is any possibility that cannabis could provide an effective treatment, that possibility should be thoroughly and appropriately investigated.
Medical cannabis is now legal in Pennsylvania, but there is still work to be done. CAMO is working to coordinate and support cannabis research throughout the state. We are in the process of securing one of Pennsylvania’s Research Affiliation Licenses.
Upon approval, we will work with an institution of medical education and a hospital system to conduct research on one or more of the state approved qualifying conditions.